Marks Gilbert Lynn 4

What Happened
Marks Gilbert Lynn, a director of AN2 Therapeutics, received an award of 2,789 shares on 2026-07-10. The reported acquisition price is $0.00 (shares issued in lieu of cash compensation), and the filing indicates all shares vested immediately.

Key Details

• Transaction date: 2026-07-10; transaction type: Award/Grant (code A)
• Shares received: 2,789; price per share reported: $0.00; total reported cash value: $0
• Footnote: Shares issued in lieu of cash under the issuer’s non-employee director compensation policy; all shares vest immediately (Footnote F1)
• Shares owned after transaction: not specified in the filing summary provided
• Filing timeliness: Report filed with SEC on 2026-07-10 (period of report 2026-07-10), indicating a timely Form 4

Context
This was a compensation grant (shares issued instead of cash) rather than an outright market purchase or sale. Such awards compensate directors and do not necessarily signal the director buying additional stock; immediate vesting means there are no remaining service conditions attached to these shares.